Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2016, Article ID 1390571, 11 pages
http://dx.doi.org/10.1155/2016/1390571
Research Article

miR-125b and miR-100 Are Predictive Biomarkers of Response to Induction Chemotherapy in Osteosarcoma

1Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
2Division of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
3Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
4Pathology and Clinical Laboratory Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
5Division of Cancer Genomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
6Department of Functional Analysis, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

Received 11 July 2016; Revised 4 October 2016; Accepted 18 October 2016

Academic Editor: Valerae O. Lewis

Copyright © 2016 Daisuke Kubota et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. P. Gibbs, K. Weber, and M. T. Scarborough, “Malignant bone tumors,” Journal of Bone and Joint Surgery—Series A, vol. 83, no. 11, pp. 1728–1745, 2001. View at Google Scholar · View at Scopus
  2. P. A. Meyers and R. Gorlick, “Osteosarcoma,” The Pediatric Clinics of North America, vol. 44, no. 4, pp. 973–989, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. A. J. Provisor, L. J. Ettinger, J. B. Nachman et al., “Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group,” Journal of Clinical Oncology, vol. 15, no. 1, pp. 76–84, 1997. View at Google Scholar · View at Scopus
  4. G. Rosen, “Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience,” Orthopedics, vol. 8, no. 5, pp. 659–664, 1985. View at Google Scholar · View at Scopus
  5. G. Rosen, R. C. Marcove, A. G. Huvos et al., “Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy,” Journal of Cancer Research and Clinical Oncology, vol. 106, no. 1, pp. 55–67, 1983. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Rosen, B. Caparros, S. Groshen et al., “Primary osteogenic sarcoma of the femur: a model for the use of preoperative chemotherapy in high risk malignant tumors,” Cancer Investigation, vol. 2, no. 3, pp. 181–192, 1984. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Bacci, M. Avella, D. P. A. Brach et al., “Neoadjuvant chemotherapy for osteosarcoma of the extremities. Good response of the primary tumor after preoperative chemotherapy with high-dose methotrexate followed by cisplatinum and adriamycin. Preliminary results,” Chemioterapia, vol. 7, no. 2, pp. 138–142, 1988. View at Google Scholar · View at Scopus
  8. K. Winkler, G. Beron, G. Delling et al., “Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response,” Journal of Clinical Oncology, vol. 6, no. 2, pp. 329–337, 1988. View at Google Scholar · View at Scopus
  9. A. M. Davis, R. S. Bell, and P. J. Goodwin, “Prognostic factors in osteosarcoma: a critical review,” Journal of Clinical Oncology, vol. 12, no. 2, pp. 423–431, 1994. View at Google Scholar · View at Scopus
  10. S. Weeden, R. J. Grimer, S. R. Cannon, A. H. M. Taminiau, and B. M. Uscinska, “The effect of local recurrence on survival in resected osteosarcoma,” European Journal of Cancer, vol. 37, no. 1, pp. 39–46, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Bacci, A. Longhi, M. Versari, M. Mercuri, A. Briccoli, and P. Picci, “Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution,” Cancer, vol. 106, no. 5, pp. 1154–1161, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. S. S. Bielack, B. Kempf-Bielack, G. Delling et al., “Prognostic factors in high-grade osteosarcoma of the extremities or trunk. An analysis of 1702 patients treated on Cooperative Osteosarcoma Study Group protocols,” Journal of Clinical Oncology, vol. 20, no. 3, pp. 776–790, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. D. B. Glasser, J. M. Lane, A. G. Huvos, R. C. Marcove, and G. Rosen, “Survival, prognosis, and therapeutic response in osteogenic sarcoma. The memorial hospital experience,” Cancer, vol. 69, no. 3, pp. 698–708, 1992. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Akatsuka, T. Wada, Y. Kokai et al., “ErbB2 expression is correlated with increased survival of patients with osteosarcoma,” Cancer, vol. 94, no. 5, pp. 1397–1404, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Baldini, K. Scotlandi, G. Barbanti-Bròdano et al., “Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome,” The New England Journal of Medicine, vol. 333, no. 21, pp. 1380–1385, 1995. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Rosen, B. Caparros, A. G. Huvos et al., “Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy,” Cancer, vol. 49, no. 6, pp. 1221–1230, 1982. View at Publisher · View at Google Scholar · View at Scopus
  17. M. J. Klein and G. P. Siegal, “Osteosarcoma: anatomic and histologic variants,” American Journal of Clinical Pathology, vol. 125, no. 4, pp. 555–581, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. M. L. Kuijjer, P. C. W. Hogendoorn, and A.-M. Cleton-Jansen, “Genome-wide analyses on high-grade osteosarcoma: making sense of a genomically most unstable tumor,” International Journal of Cancer, vol. 133, no. 11, pp. 2512–2521, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. A. K. Boehm, J. R. Neff, J. A. Squire, J. Bayani, M. Nelson, and J. A. Bridge, “Cytogenetic findings in 36 osteosarcoma specimens and a review of the literature,” Pediatric Pathology and Molecular Medicine, vol. 19, no. 5, pp. 359–376, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Kikuta, N. Tochigi, S. Saito et al., “Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics,” Proteomics—Clinical Applications, vol. 4, no. 5, pp. 560–567, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Kubota, K. Mukaihara, A. Yoshida, H. Tsuda, A. Kawai, and T. Kondo, “Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma,” Journal of Proteomics, vol. 91, pp. 393–404, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. B. P. Lewis, C. B. Burge, and D. P. Bartel, “Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets,” Cell, vol. 120, no. 1, pp. 15–20, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. L. P. Lim, N. C. Lau, P. Garrett-Engele et al., “Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs,” Nature, vol. 433, no. 7027, pp. 769–773, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. R. R. Lulla, F. F. Costa, J. M. Bischof et al., “Identification of differentially expressed microRNAs in osteosarcoma,” Sarcoma, vol. 2011, Article ID 732690, 6 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Maire, J. W. Martin, M. Yoshimoto, S. Chilton-MacNeill, M. Zielenska, and J. A. Squire, “Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma,” Cancer Genetics, vol. 204, no. 3, pp. 138–146, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Kobayashi, R. Satow, M. Ono et al., “MicroRNA expression and functional profiles of osteosarcoma,” Oncology, vol. 86, no. 2, pp. 94–103, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. K. B. Jones, Z. Salah, S. Del Mare et al., “miRNA signatures associate with pathogenesis and progression of osteosarcoma,” Cancer Research, vol. 72, no. 7, pp. 1865–1877, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. M. B. Mintz, R. Sowers, K. M. Brown et al., “An expression signature classifies chemotherapy-resistant pediatric osteosarcoma,” Cancer Research, vol. 65, no. 5, pp. 1748–1754, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Gougelet, D. Pissaloux, A. Besse et al., “Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response,” International Journal of Cancer, vol. 129, no. 3, pp. 680–690, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. A. D. Kelly, B. Haibe-Kains, K. A. Janeway et al., “MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32,” Genome Medicine, vol. 5, no. 1, article 2, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Iwamoto, K. Tanaka, K. Isu et al., “Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J,” Journal of Orthopaedic Science, vol. 14, no. 4, pp. 397–404, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Ishiyama, Y. Miyazono, K. Sasamoto, Y. Ohkura, and K. Ueno, “A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability,” Talanta, vol. 44, no. 7, pp. 1299–1305, 1997. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Bacci, S. Ferrari, N. Delepine et al., “Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin,” Journal of Clinical Oncology, vol. 16, no. 2, pp. 658–663, 1998. View at Google Scholar · View at Scopus
  35. D. Borys, R. J. Canter, B. Hoch et al., “P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy,” Human Pathology, vol. 43, no. 11, pp. 1948–1954, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Huang, K. Gao, J. Lin, and Q. Wang, “MicroRNA-100 inhibits osteosarcoma cell proliferation by targeting Cyr61,” Tumor Biology, vol. 35, no. 2, pp. 1095–1100, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. L.-H. Liu, H. Li, J.-P. Li et al., “miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3,” Biochemical and Biophysical Research Communications, vol. 416, no. 1-2, pp. 31–38, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. W. Lu, Y. Zuo, Y. Feng, and M. Zhang, “SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer,” Tumor Biology, vol. 35, no. 11, pp. 10699–10705, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Igci, M. E. Kalender, E. Borazan et al., “High-throughput screening of Sirtuin family of genes in breast cancer,” Gene, vol. 586, no. 1, pp. 123–128, 2016. View at Publisher · View at Google Scholar
  40. J. George and N. Ahmad, “Mitochondrial sirtuins in cancer: emerging roles and therapeutic potential,” Cancer Research, vol. 76, no. 9, pp. 2500–2506, 2016. View at Publisher · View at Google Scholar
  41. P. Berlanga, L. Muñoz, M. Piqueras et al., “miR-200c and phospho-AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis,” Molecular Oncology, vol. 10, no. 7, pp. 1043–1053, 2016. View at Publisher · View at Google Scholar
  42. P. C. Sanchez-Diaz, T.-H. Hsiao, Y. Zou et al., “In silico functional analyses and discovery of survival-associated microRNA signatures in pediatric osteosarcoma,” Oncoscience, vol. 1, no. 9, pp. 599–608, 2014. View at Publisher · View at Google Scholar · View at Scopus